The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now allowing its use in children as young as 6 weeks old. Previously ...

Sanofi (SNY) wins FDA label expansion for its MenQuadfi meningococcal vaccine for use in infants as young as six weeks. Read more here.

MenQuadfi builds on Sanofi’s legacy at the forefront of meningococcal disease prevention beginning with the first monovalent vaccine for Africa in 1974.

Sanofi’s Meningitis Flag initiative will include out-of-home awareness messages shown at around 500 locations during the Paris 2024 Paralympic Games. The drugmaker plans to make the flag “a ...